検索結果

tment to suppress progression. Treatment generally begins with a single agent, and if the effect is insufficient, combination therapy is considered. Since this drug therapy continues throughout the pa...

tment to suppress progression. Treatment generally begins with a single agent, and if the effect is insufficient, combination therapy is considered. Since this drug therapy continues throughout the pa...

Product Development Policy | Research & Development | SENJU Pharmaceutica

e ocular surface are used in the U.S. and EU. We consider that the current treatment issues have an insufficient effect on subjective symptoms, such as dryness, pain, and time required until the effec...